Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C16G2 Strip in dental caries
NCT03052842Phase 2Completed
- Sponsor
- Armata Pharmaceuticals
- Start
- Feb 2017
- Primary completion
- Apr 2017
- Modality
- Antimicrobial Peptides, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of C16G2 in dental caries (6 arms), sponsored by Armata Pharmaceuticals. Primary endpoints: Antimicrobial Activity of C16G2 and Total Oral Bacterial Levels. Started Feb 2017; status: completed.
02
Drugs
C16G2
03
Conditions
dental caries
Beyond the preview
Go deeper on NCT03052842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03052842.